Fulgent Genetics to acquire Inform Diagnostics from Avista Capital for $170m.

Fulgent Genetics, a technology company that focuses on genetic testing to provide physicians with clinically actionable diagnostic information, agreed to acquire Inform Diagnostics, a provider of anatomic pathology services, from Avista Capital, a private equity firm, for $170m. “We have been impressed with the Inform Diagnostics team’s commitment to quality, turnaround time, and customer service, which we believe fits well with our priorities, culture, and focus at Fulgent. We expect to see an immediate contribution from Inform Diagnostics’ mature pathology business, while in the longer term we also believe there are numerous synergies across our organizations that will drive sustained momentum across Fulgent’s core testing business. We are excited about this opportunity to drive long-term shareholder value with this strategic acquisition," Ming Hsieh, Fulgent Chairman and CEO.